3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Keratosis, Actinic
5
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Seizures
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Leukemia
1
Lennox Gastaut Syndrome
1
Head and Neck Neoplasms
1
Epilepsies, Myoclonic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Anemia
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
Cannabidiol
5
Everolimus
2
enzalutamide
1
Temozolomide
1
Standard of Care
1
Solutions
1
Lenalidomide
1
Drug Therapy
1
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Seizures
×
Solutions
×
Clear all
NCT05485831
2026-06-03
EpiTALY
Jazz Pharmaceuticals
Active not recruiting
111 enrolled